InnoCare Pharma
InnoCare Pharma is a commercial-stage biopharmaceutical company developing therapies for cancer and autoimmune diseases, listed in Hong Kong and Shanghai.
InnoCare Pharma is a dual-listed, commercial-stage biopharmaceutical company discovering, developing and commercializing therapies for cancer and autoimmune diseases. Its shares trade in Hong Kong under ticker 9969 and in Shanghai under ticker 688428, giving it access to both international and domestic capital.
Commercial execution underpins the story as annual sales of its BTK inhibitor orelabrutinib exceeded RMB 1 billion and the company reached profitability ahead of schedule. The investment case rests on marketed-product cash flow funding a late-stage pipeline led by TYK2 inhibitors and bispecific antibodies.
InnoCare markets three drugs anchored by orelabrutinib, its BTK inhibitor approved for chronic lymphocytic leukemia, mantle cell lymphoma and marginal zone lymphoma. The commercial portfolio also includes Minjuvi (tafasitamab) for diffuse large B-cell lymphoma and zurletrectinib, a ROS1 and TRK inhibitor for solid tumors.
The autoimmune pipeline is led by a pair of TYK2 inhibitors. Soficitinib (ICP-332), a TYK2-JH1 inhibitor, is in Phase III for atopic dermatitis with positive Phase II vitiligo data. Fadeucravacitinib (ICP-488), an oral TYK2-JH2 inhibitor, is in registrational Phase III development for plaque psoriasis.
InnoCare operates from its headquarters at Building 8, 8 Life Science Park Road in Beijing's ZGC Life Science Park, placing its leadership and core research inside one of China's leading biotech clusters. The Beijing base is complemented by research and manufacturing sites including Nanjing and Guangzhou, supporting an integrated discovery-to-commercialization platform.
This end-to-end footprint lets the company run global-standard clinical development while manufacturing in-house, shortening the path from trial success to market supply. Combined with dual-listing financing flexibility and partnerships spanning Greater China licensing and global out-licensing, the platform sustains a pipeline of more than ten clinical programs.
InnoCare Pharma is a commercial-stage biopharmaceutical company developing therapies for cancer and autoimmune diseases, listed in Hong Kong and Shanghai.